Tumor progression is driven by a subsequent accumulation of oncogenic mutations, such as activating mutations in KRAS and loss tumor suppressor genes such as Transforming Growth Factor β (TGFβ) and P53. The gene discussed is KRAS; the disease is neoplasm.